{"nct_id":"NCT06764875","title":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2025-03-01","start_date_type":"ACTUAL","primary_completion_date":"2029-04-27","primary_completion_date_type":"ESTIMATED","completion_date":"2030-12-09","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["AZN"]}